Arvinas Stock Today
| ARVN Stock | USD 17.67 0.92 5.49% |
PerformanceVery Weak
| Odds Of DistressLow
|
Arvinas is selling at 17.67 as of the 26th of February 2025; that is 5.49 percent increase since the beginning of the trading day. The stock's open price was 16.75. Arvinas has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of September 2018 | Category Healthcare | Classification Health Care |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut. Arvinas operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 68.77 M outstanding shares of which 10.44 M shares are presently shorted by private and institutional investors with about 12.89 trading days to cover. More on Arvinas
Moving together with Arvinas Stock
Moving against Arvinas Stock
Arvinas Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | John Houston | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsArvinas can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arvinas' financial leverage. It provides some insight into what part of Arvinas' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arvinas (ARVN) is traded on NASDAQ Exchange in USA. It is located in 5 Science Park, New Haven, CT, United States, 06511 and employs 430 people. Arvinas is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.22 B. Arvinas conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 68.77 M outstanding shares of which 10.44 M shares are presently shorted by private and institutional investors with about 12.89 trading days to cover.
Arvinas currently holds about 1.27 B in cash with (259.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Arvinas Probability Of Bankruptcy
Ownership AllocationThe majority of Arvinas outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arvinas to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arvinas. Please pay attention to any change in the institutional holdings of Arvinas as this could imply that something significant has changed or is about to change at the company.
Check Arvinas Ownership Details
Arvinas Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 1.6 M | |
| Opaleye Management Inc | 2024-12-31 | 1.6 M | |
| New Leaf Venture Partners, L.l.c. | 2024-12-31 | 1.6 M | |
| Fmr Inc | 2024-12-31 | 1.6 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.5 M | |
| Nextech Invest Ag | 2024-12-31 | 1.4 M | |
| Avidity Partners Management Lp | 2024-12-31 | 1.4 M | |
| Norges Bank | 2024-12-31 | 1.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1 M | |
| Vanguard Group Inc | 2024-12-31 | 7.1 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 6.7 M |
Arvinas Historical Income Statement
Arvinas Stock Against Markets
Arvinas Corporate Management
| CPA CPA | CFO Treasurer | Profile | |
| Ian Taylor | Chief Scientific Officer | Profile | |
| Paul McInulty | Senior Affairs | Profile | |
| Matthew JD | Gen Sec | Profile | |
| John Grosso | Senior Operations | Profile | |
| Randy Teel | Senior Development | Profile |
Already Invested in Arvinas?
The danger of trading Arvinas is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arvinas is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arvinas. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arvinas is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Arvinas offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arvinas' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arvinas Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arvinas Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arvinas. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.77) | Revenue Per Share | Quarterly Revenue Growth 1.96 | Return On Assets | Return On Equity |
The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.